Solventum Corporation $SOLV Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its stake in Solventum Corporation (NYSE:SOLV) by 30.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 643,151 shares of the company’s stock after selling 285,679 shares during the quarter. Assenagon Asset Management S.A. owned about 0.37% of Solventum worth $50,963,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Diversified Trust Co. acquired a new stake in shares of Solventum in the fourth quarter valued at about $241,000. Leverty Financial Group LLC acquired a new position in Solventum during the 4th quarter worth approximately $319,000. Gladwyn Financial Advisors Inc. boosted its holdings in Solventum by 268.8% in the 4th quarter. Gladwyn Financial Advisors Inc. now owns 686 shares of the company’s stock worth $54,000 after acquiring an additional 500 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Solventum by 12.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 54,228 shares of the company’s stock worth $4,510,000 after acquiring an additional 6,074 shares during the period. Finally, Wedmont Private Capital acquired a new stake in Solventum in the fourth quarter valued at approximately $221,000.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SOLV shares. BTIG Research reiterated a “buy” rating and set a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Stifel Nicolaus upped their target price on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. KeyCorp raised their price target on shares of Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a report on Tuesday. They issued a “sell” rating and a $60.00 price objective on the stock. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum has a consensus rating of “Hold” and an average price target of $90.64.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the purchase, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.05% of the stock is currently owned by insiders.

Solventum Stock Down 2.5%

Shares of NYSE:SOLV opened at $64.08 on Wednesday. The company’s fifty day moving average is $74.00 and its two-hundred day moving average is $75.72. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $88.20. The stock has a market capitalization of $11.12 billion, a price-to-earnings ratio of 7.22, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same period in the previous year, the business posted $1.41 EPS. The company’s quarterly revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.